SCHEMBL5540874

SCHEMBL5540874

[CH2]CCCc1nc(-c2ccc(Cl)cc2)oc1C

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.53
HSD17B10 Q99714 1/20 0.49
LMNA P02545 1/20 0.46
TARBP2 Q15633 1/20 0.46
THRB P10828 1/20 0.44
MAPT P10636 3/20 0.43
PPARG P37231 5/20 0.43
POLB P06746 4/20 0.43
TP53 P04637 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43
TSHR P16473 1/20 0.42
PPARD Q03181 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547963 0.96 PPARA (0.55) PPARAHSD17B10LMNATARBP2THRB
SCHEMBL5544253 0.91 HSD17B10 (0.51) PPARAHSD17B10LMNATARBP2THRB
SCHEMBL5537753 0.85 HRH3 (0.58) PPARAPPARGHRH3PPARD
SCHEMBL5540713 0.84 HSD17B10 (0.53) PPARAHSD17B10LMNATARBP2THRB
SCHEMBL1436227 0.82 HSD17B10 (0.54) PPARAHSD17B10LMNATARBP2THRB
SCHEMBL5544269 0.81 PPARG (0.57) PPARAPPARGHRH3PPARD
SCHEMBL13179907 0.80 HSD17B10 (0.58) PPARAHSD17B10LMNATARBP2THRB
SCHEMBL924162 0.80 HSD17B10 (0.54) PPARAHSD17B10LMNATARBP2THRB
SCHEMBL5538021 0.79 PPARG (0.59) PPARAPPARGHRH3PPARD
SCHEMBL203871 0.78 HSD17B10 (0.53) PPARAHSD17B10LMNATARBP2THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PPARA 429/4885HSD17B10 467/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.